Will J&J come up with a big enough treasure trove to win an Actelion buyout?
J&J and Actelion have made it official. The pharma giant is involved in talks to acquire the Swiss biotech, which had a market cap of $16.4 billion, before word of the buyout talks first surfaced in Bloomberg.
“There can be no assurance any transaction will result from these discussions,” notes J&J $JNJ , which could easily require up to a 50% premium to complete a deal like this. Actelion’s market cap, meanwhile, surged to about $20 billion as investors bet that a deal would come through.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.